Janet B. McGill
Washington University in St. Louis
212 Papers
924 Citations
Janet B. McGill is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 61, co-authored 182 publications.
Chat about Author
Papers
Effect of Ruboxistaurin on Albuminuria and Estimated GFR in People With Diabetic Peripheral Neuropathy: Results From a Randomized Trial
Katherine R. Tuttle,Janet B. McGill,Edward J. Bastyr,Keri Kles Poi,Nazila Shahri,Pamela W. Anderson +5 more
TL;DR: The eGFR Study was funded by the National Health and Medical Research Council and additional support from Kidney Health Australia, NHMRC#320860, the Colonial Foundation, Diabetes Australia Research Trust, and the Rebecca L. Cooper Foundation.
25
Hypoglycaemia is reduced with use of inhaled Technosphere® Insulin relative to insulin aspart in type 1 diabetes mellitus
Elizabeth R. Seaquist,Lawrence Blonde,Janet B. McGill,Simon Heller,David M. Kendall,J. B. Bumpass,Frank Pompilio,Marshall Grant +7 more
TL;DR: To evaluate the effect of final HbA1c levels on the incidences of hypoglycaemia in participants with type 1 diabetes treated with inhaled Technosphere® Insulin or subcutaneous insulin aspart, reported in alignment with the International Hypoglycaemic Study Group recommendations.
21
ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD
David M. Charytan,Scott D. Solomon,Peter Ivanovich,Giuseppe Remuzzi,Mark E. Cooper,Janet B. McGill,Hans-Henrik Parving,Patrick S. Parfrey,Ajay K. Singh,Emmanuel A. Burdmann,Andrew S. Levey,Dick de Zeeuw,Kai-Uwe Eckardt,John J.V. McMurray,Brian Claggett,Eldrin F. Lewis,Marc A. Pfeffer +16 more
TL;DR: Most ESRD cases occurred in individuals without intercurrent CV events who had lower eGFRs than individuals with intercurrentCV events, but similar post-ESRD mortality, underscoring the need for kidney-specific therapies in addition to treatment of CV risk factors to lower E SRD incidence in diabetes.
21
A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group.
TL;DR: A placebo-controlled, double-blind clinical trial has been initiated to determine whether angiotensin-converting enzyme inhibitor (ACEI) therapy with captopril (25 mg three times daily) slows the progressive loss of renal function in patients with type 1 diabetes mellitus.
20
Pharmacotherapy in Type 2 Diabetes: A Functional Schema for Drug Classification
TL;DR: In this article, the authors surveyed contemporary and historical literature to document changes in awareness of toxicity from hyperglycemia and consequent changes in treatment strategy, with the goal of proposing a useful schema for classification.
20